SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
CIPHERGEN BIOSYSTEMS, INC.
(Name of Issuer)
Common Stock, $.001 Par Value
(Title of Class of Securities)
17252Y 10 4
(CUSIP Number)
Check the following box if a fee is being paid with this statement [ ]. (A fee
is not required only if the filing person: (1) has a previous statement on the
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has no amendment subsequent thereto
reporting beneficial ownership of five percent or less of such class.) (See Rule
13d-7.)
*The remainder of this cover page shall be filled our for a reporting person's
initial filing of this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
(Continued on following page(s))
CUSIP NO. 17252Y 10 4
17252Y 10 4 13G
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
GlaxoSmithKline plc
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
England and Wales
5 SOLE VOTING POWER
NUMBER OF 1,941,162
SHARES
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY
EACH
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON 1,941,162
WITH
8 SHARED DISPOSITIVE POWER
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,941,162
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[ ]
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.2%
12 TYPE OF REPORTING PERSON*
CO
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP NO. 17252Y 10 4 13G
Item 1. (a). Name of Issuer:
(b). Address of Issuer's Principal Executive Offices:
Item 2. (a). Names of Person Filing:
GlaxoSmithKline plc
(b). Address of Principal Business Office:
980 Great West Road
Brentford
Middlesex
TW8 9GS ENGLAND
(c). Citizenship:
England and Wales
(d). Title of Class of Securities:
(e). CUSIP Number:
Item 3. Not Applicable.
Item 4. Ownership.
The information in items 1 and 5 through 11 on the
cover pages (page 2) on Schedule 13G is hereby
incorporated by reference.
Item 5. Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact
that as of the date hereof the reporting person has
ceased to be the beneficial owner of more than five
percent of the class of securities, check the
following [ ].
Item 6. Ownership of More Than Five Percent on Behalf of
Another Person:
S.R. One, Limited ("SRO") is an indirect,
wholly-owned subsidiary of Reporting Person and owner
of record of 1,941,162 Ciphergen shares:
SRO sold 9,675 shares on March 12, 2001. In July
2001, SRO exercised stock options to acquire 6,450
shares. Options over another 2,150 shares lapsed as
those options were not vested on the date that the
SRO representative resigned from the Issuer's Board
of Directors.
Item 7. Identification and Classification of Subsidiaries
Which Acquired the Security Being Reported on by the
Parent Holding Company:
Not applicable.
Item 8. Identification and Classification of Members of the
Group:
Not applicable.
Item 9. Notice of Dissolution of Group:
Not Applicable
Item 10. Certification:
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to
above were acquired and are not held for the purpose
of or with the effect of changing or influencing the
control of the issuer of such securities and were not
acquired in connection with or as a participant in
any transaction having such purpose or effect.
Signature:
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information
set
forth in this statement is true, complete and
correct.
GLAXOSMITHKLINE PLC
By: /s/ S.M. Bicknell
-------------------
S.M. Bicknell
Company Secretary
Dated: February 13, 2002